So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

Healthcare generates massive volumes of data daily – from electronic health records and insurance claims to genomic research ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorde ...

Pfizer has partnered with ‘computation-driven’ pharmaceutical technology company XtalPi to develop a drug development and discovery platform powered by artificial intelligence (AI) ...

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage non ...

Life sciences companies’ engagement with HCPs has changed significantly in the past 12 months, as the COVID-19 pandemic struck. Restrictions to in-person face-to-face interactions have resulted ...

As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Ben Hargreaves speaks to an expert in the area to learn how ...